PERSPECTA

News from every angle

← Back to headlines

Boston Scientific and Idex Provide Positive Financial Outlooks

Boston Scientific reported positive Q2 results and expects 5-6% organic revenue growth, along with $500 million in run-rate savings by 2029. Idex also raised its organic growth outlook to 5-6% and forecasts 2026 adjusted EPS of $8.70 to $8.85.

29 Jul, 17:34 — 29 Jul, 17:34
PostShare

Sources

Showing 1 of 2 sources
seeking-alphaMixed1d ago

Idex forecasts 2026 adjusted EPS of $8.70 to $8.85 as organic growth outlook rises to 5% to 6%

Read full article →

Coverage Timeline

First report: Yahoo · 29 Jul, 15:51Full coverage: 2 · 2hWindow: 2h
Left-leaningCenterRight-leaning
Yahoo29 Jul, 15:51First to report

Boston Scientific reports positive Q2 results yet opts to trim 2026 outlook

2h later
seeking-alpha29 Jul, 17:34Latest update

Idex forecasts 2026 adjusted EPS of $8.70 to $8.85 as organic growth outlook rises to 5% to 6%

Related Stories

Philippine Lawmakers File Bills Against Electric System Loss Charges

just now

Philippine LTO Extends Permit Validity Amid Technical Issues

just now

Philippines DOTr Aims for Partial Common Station Operations by Q1 2028

just now

EFCC Boss Highlights Contract Fraud as Most Prevalent Corruption in Nigerian Public Sector

just now